Apremilast: pooled safety analysis of three phase 3, randomized, controlled trials in patients with psoriatic arthritis

被引：0

作者：

Schett, G. ^{[1
]}

Mease, P. J. ^{[2
,3
]}

Kavanaugh, A. ^{[4
]}

Adebajo, A. O. ^{[5
]}

Gomez-Reino, J. J. ^{[6
]}

Wollenhaupt, J. ^{[7
]}

Cutolo, M. ^{[8
]}

Lespessailles, E. ^{[9
]}

Shah, K.

Hu, C.

Stevens, R.

Edwards, C. ^{[10
]}

Birbara, C. ^{[11
]}

机构：

[1] Univ Erlangen Nurnberg, D-91054 Erlangen, Germany

[2] Swedish Med Ctr, Seattle, WA USA

[3] Univ Washington, Sch Med, Seattle, WA USA

[4] Univ Calif San Diego, San Diego, CA 92103 USA

[5] Univ Sheffield, Sheffield, S Yorkshire, England

[6] Hosp Clin Univ, Santiago, Spain

[7] Schon Klin Hamburg Eilbek, Hamburg, Germany

[8] Univ Genoa, Genoa, Italy

[9] Univ Orleans, Orleans, France

[10] Southampton Univ Hosp, Southampton, Hants, England

[11] Univ Massachusetts, Sch Med, Worcester, MA USA

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2013年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P012

引用

页码：6 / 6

页数：1

共 50 条

[31] Hemoglobin A1c and weight changes with apremilast in patients with psoriasis and psoriatic arthritis: Pooled laboratory analysis of the phase 3 ESTEEM and PALACE trials
Puig, Luis
Korman, Neil
Greggio, Chiara
Cirulli, Joshua
Teng, Lichen
Chandran, Vinod
Khraishi, Majed
Meht, Nehal N.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB151 - AB151
[32] Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvements In Enthesitis and Dactylitis In Patients With Psoriatic Arthritis: Pooled Results From Three Phase 3, Randomized, Controlled Trials
Gladman, Dafna D.
Mease, Philip J.
Kavanaugh, Arthur
Adebajo, Adewale O.
Gomez-Reino, Juan J.
Wollenhaupt, Juergen
Cutolo, Maurizio
Schett, Georg
Lespessailles, Eric
Shah, Kamal
Hu, ChiaChi
Stevens, Randall M.
Edwards, Christopher J.
Birbara, Charles A.
ARTHRITIS AND RHEUMATISM, 2013, 65 : S347 - S347
[33] HEMOGLOBIN A1C AND WEIGHT CHANGES WITH APREMILAST IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS: POOLED LABORATORY ANALYSIS OF THE PHASE 3 ESTEEM AND PALACE TRIALS
Puig, Luis
Korman, Neil
Greggio, Chiara
Cirulli, Joshua
Teng, Lichen
Chandran, Vinod
Khraishi, Majed
Mehta, Nehal N.
ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 14 - 15
[34] LONG-TERM SAFETY AND TOLERABILITY OF APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: A PHASE 3, RANDOMIZED, CONTROLLED TRIAL
Adebajo, A.
Wells, A.
Edwards, C.
Kivitz, A.
Bird, P.
Shah, K.
Hu, C.
Stevens, R.
Aelion, J.
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 730 - 730
[35] Apremilast, an oral phosphodiesterase 4 inhibitor, is associated with long-term (104-week) improvements in enthesitis and dactylitis in patients with psoriatic arthritis: Pooled results from three phase 3, randomized, controlled trials
Gladman, Dafna
Kavanaugh, Arthur
Adebajo, Adewale
Gomez-Reino, Juan
Wollenhaupt, Juergen
Cutolo, Maurizio
Schett, Georg
Lespessailles, Eric
McIlraith, Melissa
Hu, ChiaChi
Edwards, Christopher
Birbara, Charles
Mease, Philip
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S32 - S32
[36] APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (104-WEEK) IMPROVEMENTS IN ENTHESITIS AND DACTYLITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM THREE PHASE 3, RANDOMIZED, CONTROLLED TRIALS
Gladman, D.
Kavanaugh, A.
Adebajo, A.
Gomez-Reino, J.
Wollenhaupt, J.
Cutolo, M.
Schett, G.
Lespessailles, E.
McIlraith, M.
Hu, C.
Edwards, C.
Birbara, C.
Mease, P.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 133 - 134
[37] Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Pooled Results from Three Phase 3, Randomized, Controlled Trials
Gladman, Dafna
Mease, Phillip
Kavanaugh, Arthur
Adebajo, Adewale
Gomez-Reino, Juan
Wollenhaupt, Juergen
Cutolo, Maurizio
Schett, Georg
Lespessailles, Eric
Shah, Kamal
Hu, ChiaChi
Stevens, Randall
Edwards, Christopher
Birbara, Charles
JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1449 - 1449
[38] APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (104 WEEK) IMPROVEMENT IN FATIGUE IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED RESULTS FROM THREE PHASE III RANDOMIZED CONTROLLED TRIALS
Kavanaugh, Arthur
Gladman, Dafna D.
Edwards, Christopher J.
Poder, Airi
Liote, Frederic
Bird, Paul
Schett, Georg
McIlraith, Melissa
Teng, Lichen
Mease, Philip J.
RHEUMATOLOGY, 2016, 55 : 140 - 141
[39] Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Longterm (52-Week) Improvements in BASDAI in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase III, Randomized, Controlled Trials
Mease, Philip
Marzo-Ortega, Helena
Poder, Airi
van den Bosch, Filip
Wollenhaupt, Juergen
Lespessailles, Eric
McIlraith, Melissa
Teng, Lichen
Gladman, Dafna
Hall, Stephen
JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 925 - 926
[40] APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS OF PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIALS (PALACE 1, 2, AND 3)
Bird, P.
Blanco, F.
Kavanaugh, A.
Adebajo, A.
Edwards, C.
Crowley, J.
Stevens, R.
Hu, C.
Mease, P.
INTERNAL MEDICINE JOURNAL, 2014, 44 : 19 - 19

← 1 2 3 4 5 →